For US Healthcare Professionals only.
For patients with mild, moderate, or severe dementia of the Alzheimer’s type1
Introducing ADLARITY®, the first and only once-weekly donepezil transdermal system1,2
Not actual size.
Delivers donepezil consistently throughout the 7-day wear period1-3
Explore Corplex and PKDelivery of donepezil bypasses the GI tract and avoids first-pass hepatic metabolism3
Review safety profileFlexible application and conveniently administered without regard to food intake1
View dosing and administrationStay up to date on coverage and access for ADLARITY.
GI, gastrointestinal; PK, pharmacokinetics.
ADLARITY is indicated for the treatment of mild, moderate, and severe dementia of the Alzheimer's type.
ADLARITY is contraindicated in patients with known hypersensitivity to donepezil or to piperidine derivatives or with a history of allergic dermatitis with use of ADLARITY.
ADLARITY is indicated for the treatment of mild, moderate, and severe dementia of the Alzheimer's type.
ADLARITY is contraindicated in patients with known hypersensitivity to donepezil or to piperidine derivatives or with a history of allergic dermatitis with use of ADLARITY.
The most common adverse reactions (greater than 5% with donepezil tablets and twice the placebo rate) are nausea, diarrhea, insomnia, vomiting, muscle cramps, fatigue, and anorexia.
Cholinesterase inhibitors, including donepezil, have the potential to interfere with the activity of anticholinergic medications. A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists such as bethanechol.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/MedWatch or call 1‑800‑FDA‑1088. Please click here for Full Prescribing Information.
References: 1. ADLARITY. Prescribing information. Corium, LLC; 2022. 2. Soo LE, Amit KJ, Parminder S, inventors; Corium International, Inc, assignee. Donepezil transdermal delivery system. U.S. patent 9,993,466. June 12, 2018. 3. Data on file. Corium, LLC.